116 related articles for article (PubMed ID: 8585398)
21. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Martinez-Martin FJ; Rodriguez-Rosas H; Peiro-Martinez I; Soriano-Perera P; Pedrianes-Martin P; Comi-Diaz C
J Hum Hypertens; 2011 Jun; 25(6):346-53. PubMed ID: 21107432
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
23. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension.
Christogiannis LG; Kostapanos MS; Tellis CC; Milionis HJ; Tselepis AD; Elisaf MS
J Hum Hypertens; 2013 Jan; 27(1):44-50. PubMed ID: 22129607
[TBL] [Abstract][Full Text] [Related]
24. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
Calhoun DA; Lacourcière Y; Crikelair N; Jia Y; Glazer RD
Curr Med Res Opin; 2013 Aug; 29(8):901-10. PubMed ID: 23721363
[TBL] [Abstract][Full Text] [Related]
25. Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents.
Ahaneku JE
Acta Med Okayama; 1996 Apr; 50(2):107-10. PubMed ID: 8744936
[TBL] [Abstract][Full Text] [Related]
26. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Hsueh WA; Shojaee A; Maa JF; Neutel JM
Curr Med Res Opin; 2012 Nov; 28(11):1809-18. PubMed ID: 23072496
[TBL] [Abstract][Full Text] [Related]
29. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Hirano T; Yoshino G; Kashiwazaki K; Adachi M
Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
[TBL] [Abstract][Full Text] [Related]
30. The antihypertensive effects of doxazosin: a clinical overview.
Cox DA; Leader JP; Milson JA; Singleton W
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
32. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension.
Campo C; Segura J; Roldán C; Alcázar JM; Rodicio JL; Ruilope LM
Blood Press Suppl; 2003 Dec; 2():16-21. PubMed ID: 14761072
[TBL] [Abstract][Full Text] [Related]
33. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A
Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337
[TBL] [Abstract][Full Text] [Related]
34. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool JL
Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
[TBL] [Abstract][Full Text] [Related]
35. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
Roth EM; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
J Clin Hypertens (Greenwich); 2013 Aug; 15(8):584-92. PubMed ID: 23889722
[TBL] [Abstract][Full Text] [Related]
36. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
[TBL] [Abstract][Full Text] [Related]
38. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism.
Inukai T; Inukai Y; Matsutomo R; Okumura K; Takanashi K; Takebayashi K; Tayama K; Aso Y; Takemura Y
J Int Med Res; 2004; 32(2):206-13. PubMed ID: 15080025
[TBL] [Abstract][Full Text] [Related]
39. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
Andersen P; Seljeflot I; Herzog A; Arnesen H; Hjermann I; Holme I
J Cardiovasc Pharmacol; 1998 May; 31(5):677-83. PubMed ID: 9593066
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.
Ajayi AA; Akintomide AO
J Natl Med Assoc; 1995 Jul; 87(7):485-8. PubMed ID: 7636894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
